Bristol-Myers Squibb Co
BMY46.345USD
+0.415+0.90%
시장 운영 시간 （ET）시세는 15분 지연됩니다
94.31B시가총액
17.40P/E TTM
자세한 내용은 Bristol-Myers Squibb Co 회사
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
회사 정보
종목 코드 BMY
회사 이름Bristol-Myers Squibb Co
상장일Mar 17, 1980
CEODr. Christopher S. (Chris) Boerner, Ph.D.
직원 수34100
유형Ordinary Share
회계 연도 종료Mar 17
주소Route 206 And Province Line Road
도시PRINCETON
증권 거래소NYSE Consolidated
국가United States of America
우편 번호08543
전화16092524621
웹사이트https://www.bms.com
종목 코드 BMY
상장일Mar 17, 1980
CEODr. Christopher S. (Chris) Boerner, Ph.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
62.72K
-50.00%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
16.70K
+10.70%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
8.84K
+6.22%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
Dr. Deepak L. Bhatt, M.D.
Dr. Deepak L. Bhatt, M.D.
Independent Director
Independent Director
--
--
Mr. Phil Holzer
Mr. Phil Holzer
Senior Vice President, Controller
Senior Vice President, Controller
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
62.72K
-50.00%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
16.70K
+10.70%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
8.84K
+6.22%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
수익 분석
통화: USD마지막 업데이트: Sun, Jul 6
통화: USD마지막 업데이트: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
사업별USD
이름
수익
비율
Eliquis
3.56B
31.83%
Opdivo
2.27B
20.30%
Revlimid
936.00M
8.36%
Orencia
770.00M
6.87%
Pomalyst/Imnovid
659.00M
5.88%
Other
3.00B
26.76%
지역별USD
이름
수익
비율
United States
7.87B
70.29%
International
3.11B
27.77%
other
218.00M
1.95%
사업별
지역별
사업별USD
이름
수익
비율
Eliquis
3.56B
31.83%
Opdivo
2.27B
20.30%
Revlimid
936.00M
8.36%
Orencia
770.00M
6.87%
Pomalyst/Imnovid
659.00M
5.88%
Other
3.00B
26.76%
주식 보유 통계
마지막 업데이트: 16 hours ago
마지막 업데이트: 16 hours ago
주주
주주 유형
주주
주주
비율
The Vanguard Group, Inc.
9.53%
BlackRock Institutional Trust Company, N.A.
4.80%
State Street Global Advisors (US)
4.66%
JP Morgan Asset Management
3.43%
Capital International Investors
3.27%
Other
74.31%
주주
주주
비율
The Vanguard Group, Inc.
9.53%
BlackRock Institutional Trust Company, N.A.
4.80%
State Street Global Advisors (US)
4.66%
JP Morgan Asset Management
3.43%
Capital International Investors
3.27%
Other
74.31%
주주 유형
주주
비율
Investment Advisor
47.07%
Investment Advisor/Hedge Fund
23.94%
Research Firm
3.16%
Pension Fund
2.44%
Bank and Trust
2.19%
Sovereign Wealth Fund
1.85%
Hedge Fund
0.60%
Insurance Company
0.20%
Family Office
0.06%
Other
18.51%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
4180
1.70B
83.46%
+31.40M
2025Q1
4287
1.68B
82.63%
+10.66M
2024Q4
4261
1.65B
81.14%
+17.04M
2024Q3
4116
1.60B
78.69%
-22.73M
2024Q2
4105
1.59B
78.35%
-83.12M
2024Q1
4118
1.64B
80.97%
+13.32M
2023Q4
4115
1.60B
78.83%
-46.39M
2023Q3
4042
1.63B
77.83%
-55.50M
2023Q2
4082
1.66B
78.77%
-34.93M
2023Q1
4110
1.66B
78.74%
-34.09M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
190.47M
9.36%
+1.45M
+0.77%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
97.77M
4.8%
+752.85K
+0.78%
Mar 31, 2025
State Street Global Advisors (US)
94.83M
4.66%
-310.27K
-0.33%
Mar 31, 2025
JP Morgan Asset Management
69.89M
3.43%
+6.79M
+10.76%
Mar 31, 2025
Capital International Investors
66.47M
3.27%
+20.60M
+44.91%
Mar 31, 2025
Charles Schwab Investment Management, Inc.
60.61M
2.98%
+306.43K
+0.51%
Mar 31, 2025
Geode Capital Management, L.L.C.
45.45M
2.23%
+1.06M
+2.39%
Mar 31, 2025
Norges Bank Investment Management (NBIM)
35.18M
1.73%
+2.58M
+7.92%
Dec 31, 2024
Columbia Threadneedle Investments (US)
29.03M
1.43%
+534.70K
+1.88%
Mar 31, 2025
Wellington Management Company, LLP
23.73M
1.17%
+17.75M
+296.96%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Wed, Aug 6
마지막 업데이트: Wed, Aug 6
이름
비율
First Trust NASDAQ Pharmaceuticals ETF
5.91%
LSV Disciplined Value ETF
4.06%
iShares U.S. Pharmaceuticals ETF
3.88%
Coastal Compass 100 ETF
3.81%
Schwab U.S. Dividend Equity ETF
3.57%
Cullen Enhanced Equity Income ETF
3.33%
SPDR S&P Pharmaceuticals ETF
3.26%
Tema Oncology ETF
3.16%
VanEck Pharmaceutical ETF
3.1%
Brookstone Value Stock ETF
3%
더 보기
First Trust NASDAQ Pharmaceuticals ETF
비율5.91%
LSV Disciplined Value ETF
비율4.06%
iShares U.S. Pharmaceuticals ETF
비율3.88%
Coastal Compass 100 ETF
비율3.81%
Schwab U.S. Dividend Equity ETF
비율3.57%
Cullen Enhanced Equity Income ETF
비율3.33%
SPDR S&P Pharmaceuticals ETF
비율3.26%
Tema Oncology ETF
비율3.16%
VanEck Pharmaceutical ETF
비율3.1%
Brookstone Value Stock ETF
비율3%
주식 배당금
지난 5년 동안 총
22.71B
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
Dec 11, 2024
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option
Jan 03, 2025
Feb 03, 2025
Jan 03, 2025
Sep 10, 2024
BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option
Oct 04, 2024
Nov 01, 2024
Oct 04, 2024
Jun 18, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option
Jul 05, 2024
Aug 01, 2024
Jul 05, 2024
Mar 01, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option
Apr 05, 2024
May 01, 2024
Apr 04, 2024
Dec 06, 2023
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option
Jan 05, 2024
Feb 01, 2024
Jan 04, 2024
Sep 20, 2023
BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023
Oct 06, 2023
Nov 01, 2023
Oct 05, 2023
Jun 14, 2023
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Aug 01, 2023 going ex on Jul 06, 2023 with reinvestment option
Jul 07, 2023
Aug 01, 2023
Jul 06, 2023
Mar 03, 2023
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on May 01, 2023 going ex on Apr 06, 2023
Apr 10, 2023
May 01, 2023
Apr 06, 2023
Dec 08, 2022
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Feb 01, 2023 going ex on Jan 05, 2023
Jan 06, 2023
Feb 01, 2023
Jan 05, 2023
Sep 14, 2022
BMY.NB Final Cash Dividend of gross USD 0.54 paid on Nov 01, 2022 going ex on Oct 06, 2022
Oct 07, 2022
Nov 01, 2022
Oct 06, 2022
더 보기
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
